Drug Profile


Alternative Names: BAY 865258; Dinagest; Endometrion®; M 18575; MJR-35; SH T00660AA; STS 557; Visanne

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Mochida Pharmaceutical
  • Class Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Testosterone congeners
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Contraception; Endometriosis; Menopausal syndrome
  • Phase III Adenomyosis
  • Phase II Dysmenorrhoea

Most Recent Events

  • 30 Nov 2016 Mochida completes a phase II trial in Dysmenorrhoea in Japan (PO) (JapicCTI152977)
  • 31 Jul 2015 Phase-II clinical trials in Dysmenorrhoea in Japan (PO) (JapicCTI152977)
  • 03 Feb 2015 Launched for Endometriosis in Argentina, Norway, Hong Kong and Malaysia (PO) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top